semaj83/ctmatch_classification huggingface dataset:
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 21.0-70.0,  Primary Insomnia age 21-70 yrs non-pregnant females who agree to standard birth control for 12 months and males two of the following chronic insomnia complaints: >30 min sleep latency, < 6 hrs sleep, or nonrestorative sleep meet DSM-IV for primary insomnia  any acute or unstable illness: conditions making it unsafe for the subject to participate, conditions with a potential to disturb sleep (i.e. acute pain, respiratory infection), and conditions which could interact with the pharmacokinetics or pharmacodynamics of zolpidem chronic illnesses: renal failure, liver disease, seizures, and dementing illnesses current psychiatric diseases: alcohol or substance abuse, depression, and schizophrenia a history of alcohol or substance abuse within the past two years a prestudy positive urine drug screen consuming >14 standard (1oz) alcoholic drinks per week caffeine consumption >300 mg/day smoking during the night (11pm-7am) medications including: anxiolytics, hypnotics. both prescription and OTC, (except in the chronic zolpidem group), antidepressants, anticonvulsants, sedating H1 antihistamines (non-sedating second generation H1 antihistamines are allowed), systemic steroids, respiratory stimulants and decongestants, prescription and OTC stimulants, prescription and OTC diet aids, herbal preparations, and narcotic analgesics. All medications and doses will be documented sleep disordered breathing (SDB) defined as >10 apnea-hypopneas events per hour of sleep time or any other primary sleep (e.g., restless legs syndrome) or circadian disorder
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Bipolar Disorder Have a diagnosis of bipolar disorder Be 18 years or older Be a biological parent of a child who is younger than 30 years old Be willing to participate in the survey The participant must be (or must have been) the primary caretaker for his or her child  A participant must meet criteria A participant s child cannot have been diagnosed with a mood disorder or other serious psychiatric disorder A participant s child cannot have been adopted The participant s child cannot be 30 years of age or older
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Schizophrenia Diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform Females who participate in this study are unable to have children-OR- are willing to remain abstinent from Day -5 until 90 days after discharge Males must be willing to remain sexually abstinent or use an effective method of birth control (e.g. condom) from Day -5 until 90 days after discharge Able and agree to remain off of prior antipsychotic medication for the duration of the study  Presence or history (within the last year) of a medical or surgical condition (e.g. gastrointestinal disease) that might interfere with the absorption, metabolism, or excretion of orally administered lurasidone Positive test results within 30 days prior to the start of the study for Participated in another clinical trial or receiving an investigational product within 30 days prior to drug administration Use of concomitant medications that prolong the QT/QTc interval within 14 days prior to Day to follow-up Use of a monoamine oxidase inhibitor within 21 days prior to Day 1 to Restabilization Received depot neuroleptics unless the last injection was at least 1 treatment cycle before Day -5
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 14.0-45.0,  Schizophreniform Disorder Bipolar I Disorder Bipolar II Disorder Major Depressive Disorder With Psychotic Features, Substance-Induced Psychoses Psychosis Not Otherwise Specified Schizophrenia Schizoaffective Disorder Age between 14 and 45 years (inclusive) Male or Female gender DSM-IV-TR diagnosis of Schizophrenia, Schizoaffective disorder,Schizophreniform Disorder, Bipolar Disorder (Type I),Bipolar Disorder (Type II), Major Depressive Disorder With Psychotic Features, Substance-Induced Psychoses, Psychosis Not-Otherwise-Specified (NOS) Outpatient status at the time of randomization Duration of antipsychotic treatment of less than 5 years Ability to provide informed consent Female patients of childbearing potential must be using a medically accepted means of contraception Treatment with olanzapine, clozapine, quetiapine,risperidone or paliperidone for less than 8 weeks duration at enrollment BMI between 18.5 and 30  Inability to give informed consent Currently enrolled in a weight management program Currently being treated with a medication to reduce weight Patients with unstable or active cardiovascular illnesses (myocardial infarction, congestive heart failure, etc), active or end-stage renal disease, and unstable thyroid disease, etc Inclusion/ has been intentionally limited in order to maximize the generalizability of the study
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Nicotine Dependence Structured Clinical Interview (SCID) derived DSM-IV diagnoses of Bipolar Disorder (Type I or II), and Nicotine Dependence Young Mania Rating Scale Total Score <12 at study entry HAM-D 17-Item Score >5 and <24 at study entry Fagerstrom Test for Nicotine Dependence (FTND) score of 5 or higher Be able to provide informed consent to participate in this study as judged by clinical evaluation, and scoring at least 80% on a post-consent "test" Smoking at least 10 cigarettes per day (confirmed by an expired breath CO level >10 ppm and a plasma cotinine level >150 ng/ml at baseline) Be motivated to quit smoking within 30 days of initial evaluation, as assessed by a score of 7 or higher on the Contemplation Ladder assessment tool On a stable dose of a mood stabilizer for at least 1 month (e.g. lithium, valproate, carbamazepine, atypical antipsychotic) Judged by the study psychiatrists and/or trained psychiatric clinicians to be in remission from active manic, hypomanic, major depressive and psychotic symptoms based on a clinical interview and SCID-IV ≥1 month prior to study enrollment  Meet for current abuse or dependence for any other alcohol or illicit substance within the past 3 months of study enrollment Current evidence by SCID-IV and clinical evaluation of suicidality, homicidality or psychosis Meet DSM-IV for current major depression at the time of baseline evaluation A history of hypersensitivity or other known adverse reactions (e.g. hyperstimulation, severe agitation) to varenicline Serious medical conditions (i.e. a history of severe cardiac, renal or hepatic disease, diabetes mellitus or thyroid abnormalities) EKG abnormalities Prescription of Nicotine Replacement Therapies (NRTs) including patches, gum, lozenges or inhalers Prescription of monoamine oxidase inhibitors (MAO-I's) including selegiline or moclobemide Prescription of varenicline Prescription of bupropion SR
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Weight Gain non-smoking, adults < 16 weeks gestation  medical comorbidities
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 19.0-65.0,  Major Depressive Disorder Suicidality 19-65 years of age Diagnosis of major depressive disorder Currently experiencing suicidal thoughts  Depressed patients without suicidality Patients with severe psychotic features or with primary diagnoses of bipolar disorder, schizoaffective disorder, schizophrenia, substance abuse/dependence or generalized anxiety Subjects who have taken lithium or an antipsychotic in the last 2 weeks pregnant women
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Sleep Memory to 50 years of age no sleep complaints or problems good sleep quality per questionnaire sufficient time in bed each night  any clinically significant unstable medical condition recent psychiatric disorder prior diagnosis or symptoms of a sleep disorder recent history of substance abuse recent use of prescription hypnotic medication or over-the-counter sleep aid recent use of psychotropic medication history of adverse reaction to benzodiazepines body mass index > 36 currently pregnant or nursing currently working rotating or night shift
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Sleep Initiation and Maintenance Disorders Primary Insomnia Diagnosis of primary insomnia based on DSM-IV (307.42) Written informed consent has been obtained  Patients with sleep apnea syndrome, narcolepsy, presence or suspicion of periodic leg movement or restless leg syndrome Patients with hepatic failure, myasthenia gravis, or hypersensitivity to zolpidem Patients who are known to be current drug or alcohol abuser or likely to concomitantly consume alcoholic beverages (more than 3 times/week) Patients who have received antihistamines or antipsychotics will not allow to discontinue the previous medication throughout the study Patients who are pregnant, lactating or intend to become pregnant during the study period Patients who have received antidepressants or anxiolytics will not allow to change the dose or discontinue the previous medication throughout the study Any clinically significant condition, which in the opinion of the investigator makes the patients unsuitable for the trial Participation in any clinical trial within 1 month prior to randomization
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Depression Anxiety Disorders Clinical diagnosis of Major Depressive Disorder or more on MADRS-S  Severe depression (more than 35 on MADRS-S or based on interview) Severe psychiatric condition (e.g. psychosis or bipolar disorder) Changed medication during the last three months
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 11.0-17.0,  Eating Disorder Male or female between 11 and 17 (less than 18) at beginning of trial Based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), patient fulfills for diagnosis of Anorexia Nervosa (of which there are two types: restricting or binge-eating/purging) or Eating Disorder Not Otherwise Specified, with a weight of less than or equal to 85% of his or her ideal body weight, as can best be determined at the time of assessment Treated by physician on the eating disorder team at the Children's Hospital of Eastern Ontario (CHEO)  Currently receiving treatment with any other antipsychotic medication, mood stabiliser, or stimulant Known diagnosis of: diabetes, impaired glucose tolerance, hyperlipidemia, hepatic dysfunction, substance dependence, narrow angle glaucoma, paralytic ileus, or pancreatitis, or any other medical illness that would be considered to significantly impact treatment or recovery from the eating disorder Any uncontrolled comorbid disease affecting any system including infectious, endocrine, renal, gastroenterologic, respiratory, cardiac, immunologic, or hematologic. Potential participants with controlled comorbidities in these areas may be invited to participate at the discretion of the primary investigator Experienced one or more seizures without clear and resolved etiology Inability to comply with trial requirements including lack of comprehension of English Pregnant or breast-feeding High blood pressure Known allergy or known sensitivity to products in olanzapine Other unspecified reasons that, in the opinion of the investigator, amke the patient unsuitable for enrollment Officially declared incapable of consenting to treatment under the Mental Health Act (Note: If a patient is involuntarily hospitalized, he or she can be invited to participate provided that he or she has not officially been deemed incapable of making treatment decision under the Mental Health Act)
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 30.0-65.0,  Multiple Sclerosis Diagnosis of a progressive subtype of multiple sclerosis by revised 2005 McDonald Criteria EDSS of 3.0-6.5 Ages 30-65 Must be mentally capable of providing informed consent and following study guidelines  Relapse or steroid treatment within 1 month of trial entry Any current or previous treatment with mitoxantrone, azathioprine, methotrexate, mycophenolate, cyclophosphamide, or any experimental therapy Women who are pregnant, wishing to become pregnant in the coming 30 months, or are breastfeeding Sexually active women unwilling to use reliable contraception (oral contraceptives, condom, IUD) Patients with known kidney dysfunction or creatinine >1.4; known cardiac arrhythmia or significant conduction abnormality on EKG; uncontrolled thyroid disease or TSH >20% above the upper limit of normal; uncontrolled psoriasis, HIV, or any other severe medical condition Patients with a history of unstable psychiatric illness or active severe depression Patients with a history of seizure Concurrent use of any of the following medications: Antipsychotics, diuretics, digoxin, or iodide salts Use of non-steroidal anti-inflammatory drugs (NSAIDs) 5 or more days a week Patients with a history of substance abuse in the past year
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Medication Adherence Bipolar Disorder Diagnosis of Type I or II BD for at least 6 months (confirmed with MINI) On maintenance evidence-based treatment for BD (lithium, antipsychotic, anticonvulsant) Have weight gain concerns that individual believes are related to BD medication treatment Sub-optimal adherence as measured by the Tablet Routines Questionnaire (TRQ) and which the patient feels is related to weight gain concerns. TRQ threshold will be defined as missing an average of 20% or more of all prescribed BD treatment in the last week or month or missing 20% or more of the "offending agent" in the last week or last month. This is consistent with methodologies in PIs previous BD adherence studies  Known resistance or intolerance to ziprasidone Medical contraindication to ziprasidone Individuals on ziprasidone immediately prior to study enrollment Prior or current treatment with clozapine Diagnosis of eating disorder Individuals whose sub-optimal adherence is related to inability to pay for BD medication treatment or inability to arrange transportation to BD treatment clinical visits Concurrent medical condition or psychiatric illness, which in the opinion of the research psychiatrist, would interfere with the patient's ability to participate in the trial Current substance dependence High risk of harm to self or others Female who is currently pregnant or breastfeeding
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Depression With Prominent Agitation Male or female Age 18 to 65 Outpatient at enrolment A diagnosis of major depressive disorder Baseline HAMD-17 score > 20 and HAMD Item1 score > 2 both at enrolment and baseline Significant agitation CGI-S score > 4 at screening and baseline Negative serum pregnancy test at enrolment and use of a reliable method of birth control during the study Able to understand and comply with the requirements of the study Able and willing to give meaningful informed written consent  Another Axis I diagnosis of primary focus within 6 months of enrolment Axis II disorder causing impact on current diagnosis Current depressive episode <4 weeks, or >12 months Substance or alcohol abuse or dependency as defined by DSM IV within 6 months of enrolment Any pervasive developmental disorder or dementing disorder Treatment with other antipsychotics, mood stabilizer or other psychoactive drugs less than 7 days prior to randomization Treatment with fluoxetine less than 28 days prior to baseline Treatment with MAO inhibitors, anxiolytic drugs in excess of 2 mg lorazepam equivalents/day Insufficient response to more than two antidepressants during the index episode prior to study involvement Known lack of antidepressant response to quetiapine at a dose of at least 50 mg/day x 4 weeks